美金刚联合西酞普兰对阿尔茨海默病伴精神行为症状及认知功能的影响
Effect of memantine combined with citalopram on psychobehavioral symptoms and cognitive function in patients with Alzheimers disease
ES评分 0
| DOI |
| 刊名 |
Journal of International Psychiatry
|
| 年，卷(期) |
2023, 50(5) |
| 作者 |
|
| 作者单位 |
四川省南充精神卫生中心 ;
|
| 摘要 |
摘要：目的：探讨美金刚联合西酞普兰对阿尔茨海默病伴精神行为症状及认知功能的影响及其作用机制。方法：选择2020年1月至2022年3月我院接诊的88例AD患者进行研究。采用随机数字表法将患者分为2组，每组各44例。对照组予盐酸美金刚片，观察组在此基础上加以氢溴酸西酞普兰片。比较2组患者临床疗效、精神行为症状、认知功能、ERK1/2、CREB、突触可塑性相关指标及不良反应发生情况。结果：观察组总有效率为90.91%，高于对照组的75.00%（P<0.05）。治疗后两组患者MMSE得分均高于治疗前，且观察组高于对照组；治疗后两组患者BEHAVE-AD、NPI-Q得分均低于治疗前，且观察组低于对照组（P<0.05）。治疗后两组患者ERK1/2、CREB水平均高于治疗前，且观察组高于对照组（P<0.05）。治疗后两组患者GAP- 43、Nogo-A表达灰度值均高于治疗前，且观察组均高于对照组（P<0.05）。对照组共出现6例（13.64%）不良反应，观察组共出现8例（18.18%）不良反应，两组差异无统计学意义（P>0.05）。结论：美金刚联合西酞普兰治疗较单独使用美金刚可有效改善阿尔茨海默病患者精神行为症状及认知功能，其机制可能与激活ERK1/2、CREB信号通路，上调GAP- 43、Nogo-A表达有关。
|
| Abstract |
Abstract: Objective: To investigate the effect of memantine combined with citalopram on psychobehavioral symptoms and cognitive function in patients with Alzheimers disease and its mechanism.Methods: 88 AD patients from January 2020 to March 2022 were selected for study.The patients were randomly divided into two groups with 44 patients in each group.The control group was given memantine hydrochloride tablets, and the observation group was given citalopram hydrobromide tablets on this basis. The clinical efficacy, psychobehavioral symptoms, cognitive function, ERK1/2, CREB, synaptic plasticity and adverse reactions of the two groups were compared.Results: The total effective rate of the observation group was 90.91%, higher than that of the control group 75.00%(P<0.05).The MMSE scores of patients in both groups after treatment were higher than those before treatment, and those in the observation group were higher than those in the control group; After treatment, the scores of BEHAVE-AD and NPI-Q in the two groups were lower than those before treatment, and those in the observation group were lower than those in the control group (P<0.05). The ERK1/2 and CREB levels in the two groups after treatment were higher than those before treatment, and those in the observation group were higher than those in the control group (P<0.05). After treatment, the grayscale values of GAP 43 and Nogo-A expressions in the two groups were higher than those before treatment, and those in the observation group were higher than those in the control group (P<0.05).There were 6 cases (13.64%) of adverse reactions in the control group, and 8 cases (18.18%) in the observation group. There was no significant difference between the two groups (P>0.05).Conclusion: Memantine combined with citalopram can effectively improve the psychobehavioral symptoms and cognitive function of Alzheimers disease patients compared with memantine alone. Its mechanism may be related to activating ERK1/2 and CREB signal pathways and up regulating the expression of GAP 43 and Nogo-A.
|
| 关键词 |
美金刚；西酞普兰；阿尔茨海默病；精神行为症状；认知功能
|
| KeyWord |
Memantine; Citalopram; Alzheimers Disease; Psychobehavioral Symptoms; Cognitive Function
|
| 基金项目 |
|
| 页码 |
1040-1044 |
杜晓莉*.
美金刚联合西酞普兰对阿尔茨海默病伴精神行为症状及认知功能的影响 [J].
国际精神病学杂志.
2023; 50; (5).
1040 - 1044.